Unauited Financial Results along with Limited Review Report for the quarter ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 0.5 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Arunjyoti Bio Ventures reported Q3 FY26 revenue of ₹646.82 lakhs, a sequential recovery from ₹533.65 lakhs in Q2 FY26 and slightly above ₹615.38 lakhs in Q3 FY25. For the nine months ended December 2025, revenue stood at ₹2,051.71 lakhs, down about 9% from ₹2,260.30 lakhs in the same period last year. The company swung to a profit after tax of ₹4.87 lakhs in Q3 FY26, compared to a loss of ₹88.76 lakhs in Q3 FY25, while 9-month PAT rose to ₹86.48 lakhs from ₹74.90 lakhs. Total expenses fell sharply on a nine-month basis, helping margins recover. Auditor PKF Sridhar & Santhanam LLP issued an unmodified review report with an emphasis of matter on a prior-period deferred tax correction under Ind AS 8, and noted that prior period figures were reviewed/audited by a predecessor auditor.
The turnaround to a small quarterly profit and the 15% rise in nine-month PAT are mildly positive, but nine-month revenue is still shrinking and earnings remain thin relative to the equity base. The auditor change and the restatement of prior deferred tax figures add a layer of caution for investors.